Patents by Inventor Coleman Gross

Coleman Gross has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Optimizing mifepristone levels for Cushing's patients
    Patent number: 11173165
    Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: November 16, 2021
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Joseph Belanoff, Coleman Gross
  • OPTIMIZING MIFEPRISTONE LEVELS FOR CUSHING'S PATIENTS
    Publication number: 20200261471
    Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.
    Type: Application
    Filed: May 5, 2020
    Publication date: August 20, 2020
    Inventors: Joseph Belanoff, Coleman Gross
  • Optimizing mifepristone levels for cushing's patients
    Patent number: 10660904
    Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: May 26, 2020
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Joseph Belanoff, Coleman Gross
  • OPTIMIZING MIFEPRISTONE LEVELS FOR CUSHING'S PATIENTS
    Publication number: 20190117671
    Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 25, 2019
    Inventors: Joseph Belanoff, Coleman Gross
  • Optimizing mifepristone levels for Cushing's patients
    Patent number: 10166242
    Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: January 1, 2019
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Joseph Belanoff, Coleman Gross
  • Optimizing mifepristone levels for cushing'S patients
    Patent number: 10166243
    Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: January 1, 2019
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Joseph Belanoff, Coleman Gross
  • OPTIMIZING MIFEPRISTONE LEVELS FOR CUSHING'S PATIENTS
    Publication number: 20180200265
    Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.
    Type: Application
    Filed: March 13, 2018
    Publication date: July 19, 2018
    Inventors: Joseph Belanoff, Coleman Gross
  • Optimizing mifepristone levels for cushing's patients
    Patent number: 9943526
    Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: April 17, 2018
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Joseph Belanoff, Coleman Gross
  • OPTIMIZING MIFEPRISTONE LEVELS FOR CUSHING'S PATENTS
    Publication number: 20160310507
    Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.
    Type: Application
    Filed: April 20, 2016
    Publication date: October 27, 2016
    Inventors: Joseph Belanoff, Coleman Gross